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Abstract
Background: Retinal angiomatous proliferation (RAP) has been known as a variant of exudative age-related
macular degeneration (AMD) with a unfavorable prognosis. To evaluate the effect of ranibizumab administered
initially as three loading doses for patients with various stages of RAP.
Methods: A retrospective chart review of 40 patients (41 eyes) with RAP was conducted. The study divided patients
into three groups of Group I (8 eyes in stage I), Group II (17eyes in stage II), and Group III (16 eyes in stage III). All
patients received three initial monthly intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly
for 12 months. Reinjection of ranibizumab after three initial monthly doses was administered on as-needed basis.
The main outcome measures were the change in the mean of best-corrected Snellen visual acuity (BCVA) and
central macular thickness (CMT), and the total number of injections received during the 12 months.
Results: The mean change in BCVA at 12 months was-0.286,-0.165, and-0.151 (logMAR) in Group I, II, and III,
respectively. CMT was also reduced by a mean of 32.72 ± 56.75, 57.45 ± 56.48 and 148.37 ± 98.59 μm. The mean
number of injections in Group I was significant lower than those in Group II and III (P < 0.001, P < 0.001, and
P = 0.15 for Group I versus Group II, Group I versus Group III, and Group II versus Group III, respectively).
Conclusions: The 12-month follow-up outcomes suggest that three consecutive loading doses of intravitreal
ranibizumab is an effective treatment on early stage (stage I) of RAP. Patients in stage I showed a significantly
lower recurrence rate than patients in later stages.
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Background
Retinal angiomatous proliferation (RAP) has been described
as a variant of exudative age-related macular degeneration
(AMD). It was first described by Yannuzzi et al [1] in 2001
and has been differentiated into 3 stages based on clinical
and angiographic observations: stage I, intraretinal neovas-
cularization (IRN) with proliferation of intraretinal capillar-
ies within the deep retinal layers, producing intraretinal and
superficial retinal hemorrhages; stage II, subretinal neovas-
cularization (SRN). SRN with retinal–retinal anastomosis is
further divided into two further categories depending on
the absence (IIA) or presence (IIB) of pigment epithelium
detachment (PED). Stage III is clinically or angiographically
observed choroidal neovascularization (CNV) with vascu-
larized PED and retinal-choroidal anastomosis.
RAP is sometimes referred to as type 3 neovasculariza-
tion to distinguish it from the Gass CNV type 1 and type 2
anatomic classifications [2]. The natural course of RAP is
believed to be worse than that of typical exudative AMD
[3]. The risk of neovascularization in the fellow eye is
higher in patients with RAP than in those with other forms
of neovascular AMD [4]. Different treatment modalities
have been proposed for RAP such as conventional laser
photocoagulation, transpupillary thermotherapy, surgical
* Correspondence: cuteyg2000@catholic.ac.kr
Department of Ophthalmology, Yeouido St. Mary’s Hospital, College of
Medicine, The Catholic University of Korea, #62 Yeouido-dong,
Yeongdeungpo-gu, Seoul 150-713, Korea
© 2015 Park and Roh. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Park and Roh BMC Ophthalmology  (2015) 15:182 
DOI 10.1186/s12886-015-0172-2
ablation, and monotherapy with photodynamic therapy
(PDT) using verteporfin (Visudyne; Novartis Pharma AG,
Basel, Switzerland), or combined PDTand intravitreal injec-
tion of triamcinolone acetonide [5–10].
Although these modalities have been used to treat RAP,
their results showed limited success or poor functional out-
comes. Vascular endothelial growth factor (VEGF) is well
known to be closely related to CNV complexes [11, 12].
Anti-VEGFs including bevacizumab (Avastin®, Genetech,
South San Francisco, California) and ranibizumab (Lucen-
tis®, Genetech, South San Francisco, California) have shown
promising results in AMD. Major clinical trials have re-
ported that ranibizumab was effective in improving visual
acuity (VA) in AMD patients [13, 14]. The demonstration
of positive immunoreactivity of VEGF in patients with RAP
supports the important role of anti-VEGF agents in treating
exudative AMD [15, 16]. Recently, several authors have
published the results of treatment of RAP with anti-VEGF
monotherapy [17–20]. A different response to treatment in
RAP compared with the response shown by typical
exudative AMD was reported because of differences in
patient’s characteristics, study design and treatment proto-
col. Although ranibizumab monothrapy did not result in a
good response in some reports, it showed promising effi-
cacy and safety for treatment of RAP in other reports. The
stage of RAP could be considered to be an important prog-
nostic factor. But few studies have determined the effect of
ranibizumab monotherapy based on the RAP stage.
In this study, we report our 1-year results of using
intravitreal ranibizumab “loading dose” monotherapy for
the treatment of RAP by investigating the change in vi-
sion, and foveal height on optical coherence tomography
(OCT). To evaluate the efficacy of ranibizumab accord-




We performed a retrospective review of the medical re-
cords of all patients who had been treated with intravitreal
ranibizumab for three consecutive months for RAP lesions
at Yeouido Saint Mary’s Hospital between January 2009
and January 2011. Inclusion criteria was age ≥ 55 years and
the presence of a typical RAP lesion, including preretinal,
intraretinal and/or subretinal hemorrhages with neovascu-
larization in one of the three stages of RAP confirmed by
high definition-optical coherence tomography (HD-OCT),
fluorescein angiography (FA) and indocyanine green angi-
ography (ICGA). Forty patients (41 eyes) with RAP were
defined with Group I (8 eyes in stage I), Group II (17 eyes
in stage II) and Group III (16 eyes in stage III) according to
a classification system proposed by Yannuzzi et al. Patients
previously treated with PDT or drugs including ranibi-
zumab were excluded from the study. The Institutional
Review Board/Ethics Committee of Yeouido St. Mary’s
Hospital approved this study (No.SC15RISI0008) and it
was performed in accordance with the tenets of the
Declaration of Helsinki. All patients provided written
informed consent.
Methods and injection procedure
At baseline, each patient underwent best-corrected Snel-
len visual acuity testing, slit lamp examination, fundus
examination, fundus fluorescein angiography (FFA), in-
docyanine green angiography (ICGA) using confocal
scanning laser ophthalmoscope (Heidelberg Engineering,
Heidelberg, Germany), and optical coherent tomography
(Cirrus HD-OCT, Carl Zeiss, Dublin, CA, USA). RAP
was diagnosed based on preoperative baseline FFA,
ICGA and HD-OCT.
All patients received a monthly injection of 0.05 mL rani-
bizumab for 3 months and were followed up monthly. All
follow-up visits included determination of best-corrected
visual acuity (BCVA) and examination to measure the
central thickness of the neurosensory retina on HD-OCT.
FFA and ICGA were performed on month 4 after three
monthly loading injections. If any signs indicating relapse
were observed on fundoscopy, FFA and ICGA were per-
formed additionally.
In all patients, the main outcome measurements included
the changes in BCVA and CMT (as documented by HD-
OCT). Central macular thickness (CMT) was defined as
the distance between the internal limiting membrane and
the RPE. The secondary outcome measurements included
persistent leakage on FFA and ICGA. Data on BCVA
changes and HD-OCT features were analyzed at the 1-, 2-,
3-, 6-and 12-month follow-up time points. Additional ‘as
needed’ injections of ranibizumab were offered at the dis-
cretion of the treating physician if a new hemorrhage was
observed during a clinical examination or if any signs indi-
cating the recurrence of RAP leakage (intraretinal edema,
intraretinal vascular anastomosis, retinal-choroidal anasto-
mosis, or the presence of pigment epithelial detachment)
was seen on OCT, FFA or ICGA examination. Subsequent
injections were given at least 4 weeks after the previous
injection.
Statistical methods
Snellen visual acuities were converted to the logarithm of
the minimum angle of resolution (logMAR) scale for
statistical analysis. A decrease in VA was defined as the
doubling of the visual angle (≥0.3 on logMAR). An in-
crease in VA was defined as the halving of the visual angle
(≤0.3 on logMAR). If the VA change was less than 0.3 on
logMAR, it was classified as stable. If the VA changed by a
smaller amount, it was classified as stable. The number of
treatments performed during the first 12 months after the
initial treatment was compared among the groups (One-
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way ANOVA on ranks). The Wilcoxon signed-rank test
was performed to compare any two time points within the
group, and an analysis of variance test was used to make a
comparison between the groups. P values of 0.05 or less
were considered to be statistically significant. Statis-
tical analysis was performed using SPSS 17.0 (SPSS,
Inc, Chicago, IL).
Results
The study included 41 eyes from 40 patients with a
mean age of 67.09 (SD 11.76) years (range, 46-87).
Table 1 shows the main baseline characteristics between
the RAP stages. Group III had a significantly lower base-
line visual acuity than Group I (P < 0.001) and Group II
(P = 0.030).
BCVA improved from the baseline to the final visit by a
mean of-0.29,-0.17,-0.15 log MAR in Group I, II, and III,
respectively. The change in mean BCVA at 12 months
after initial treatment was better than baseline BCVA in
all groups (Fig. 1). After 12 months, forty eyes of 41 eyes
(97.5 %) showed improved or maintained BCVA. Only 1
eye in Group III (2.4 %) lost 0.3 logMAR units or more of
visual acuity. Five eyes of 8 eyes (62.5 %) in group I
showed improvement in BCVA with ≥0.3 logMAR units
(Fig. 2).
The mean CMT was reduced significantly by 12 months
in group II and group III. Although mean CMT in group I
was also decreased from 254.43 ± 29.13 μm to 221.71 ±
33.17 μm, the change was not significant (P = 0.209). In
Group I, II, and III, CMT was reduced by a mean of
32.72 ± 56.75, 57.45 ± 56.48 and 148.37 ± 98.59 μm, re-
spectively. The difference in mean CMT between base-
line and the 12-month visit was 24.73 μm between
Group I and II (P = 0.662), 90.92 μm (P < 0.001)
between Group II and III, and 115.65 μm (P = 0.003)
between Group I and III (Fig. 3).
The mean number of ranibizumab injections received
by patients during the 12 months was 4.07. The mean
number of injections in Group I, Group II and Group III
after initial three consecutive doses of ranibizumab was
0.25, 1.43 and 2.18 respectively. During the 12 months
of follow-up after the initial treatment, the mean num-
ber of treatments was significantly lower in Group I than
in Group II and Group III (one-way ANOVA on ranks:
P < 0.001, P < 0.001, and P = 0.15 for Group I versus
Group II, Group I versus Group III, and Group II versus
Group III, respectively) (Fig. 4).
Seven eyes (87.5 %) in Group I did not show relapses
during the follow-up periods (Fig. 5). RAP relapses were
seen in 13 eyes (76.5 %), 12 eyes (87.5 %) in Group II
and III, respectively. One eye (6.3 %) in Group III expe-
rienced small submacular hemorrhage after injections of
ranibizumab. No eye in the three subgroups showed pro-
gression to a higher stage of RAP during the follow-up.
No major ocular injection-related adverse events, includ-
ing infectious endophthalmitis, drug-related inflammation,
retinal detachment, or significantly increased intraocular
pressure were observed during the follow-up period.
Discussion
RAP accounts for 10 % to 15 % of all neovascular AMD in
white patients, but its natural course is believed to be worse
than that of typical exudative AMD. Viola et al [3] reported
that six of nine patients with stage I and all of the patients
with stage II progressed to visual loss within 6 months.
Therefore, early recognition and proper management of
RAP are essential. Several studies have reported many treat-
ment procedures to establish the best strategy for treating
RAP lesions. Among them, anti-VEGF therapy has been
investigated in various modalities, with some treatment reg-
imens involving PDTand triamcinolone [10, 21, 22].
Rouvas et al [23, 24] reported that patients treated
with ranibizumab monotherapy, intravitreal triamcino-
lone plus PDT, or ranibizumab plus PDT resulted in
stabilization of the disease. But patients treated with the
simultaneous combination of PDT and either ranibizu-
mab or triamcinolone experienced several negative ef-
fects. PDT may increase the risk of photooxidative
damage in the retina through intraretinal activation of
extravasated verteporfin in the perifoveal cystic space
and increase the risk of a retinal pigment epithelium
tear. Blockage of VEGF by the anti-VEGF agent may
enhance and prolong the photothrombotic effects on the
physiologic choroid caused by PDT, leading to severe
choroidal ischemia [23]. Even though ranibizumab with
combined PDT therapy can lead to improved visual func-
tion, therapy using this combination may be complicated
Table 1 Baseline characteristics of patients with retinal angiomatous proliferation
Group I Group II Group III p value
Mean age (years) 64.75 ± 14.58 63.41 ± 11.04 72.18 ± 9.68 0.180
Number (Male/Female) 8 ( 4/4) 17 (7/10) 16 (5/11) 0.662
Mean BCVA (logMAR) 0.441 ± 0.24 0.602 ± 0.26 0.831 ± 0.56 0.105
Mean CMT (μm) 254.43 ± 57.29 289.78 ± 66.46 372.72 ± 127.14 0.040*
BCVA, best-corrected visual acuity; CMT, central macular thickness
*P < 0.05
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by the higher incidence of RPE tears and atrophic change
[25].
In our study, patients were scheduled to receive three
consecutive doses of intravitreal ranibizumab. Thereafter,
re-treatment with ranibizumab was performed based on
defined criterion such as the one given in the injection
schedule of PrONTO study [26]. Although the PrONTO
study did not provide separate data for patients with
RAP lesions, Fung et al [27] reported that patients with
RAP required a higher mean number of injections of
ranibizumab compared to patients with other types of
CNV in the PrONTO study.
In our results, treatment prognosis differs according to
the clinical stage of RAP during the 12 months. In
several recent reports, intravitreal ranibizumab mono-
therapy was given mostly to patients with stage II and
III RAP lesions [28, 29]. Parodi et al [30] demonstrated
that both ranibizumab and bevacizumab showed similar
efficacy in stage I and II RAP. But they did not analyse
the subgroup within the ranibizumab injection group.
Kramann et al [19] reported the short term results of
intravitreal ranibizumab for 26 eyes with RAP including
7 eyes of stage I RAP. 12 eyes had 6 months follow-up,
and 6 eyes completed 9-months follow-up. It would be
difficult to evaluate the relapse of RAP with such short
follow-up periods.
In our study, there was an improvement in visual acuity
and CMT in all groups after the intravitreal ranibizumab
injections. Although improvement of Group I showed
similar trend of ‘ceiling effect’ observed in the ANCHOR
study [31], BCVA and CMT in group I at 12 months
follow-up showed the most improvement among three
groups , resulting in the best functional and anatomical
outcomes. In addition, lower number of reinjections
Fig. 1 Change in logarithm of the minimum angle of resolution (logMAR) visual acuity over 12 months for 41 eyes treated with an intravitreal
injection of ranibizumab according to stage
Fig. 2 One year results of best-corrective visual acuity (log MAR) change in three groups after ranibizumab injections
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needed in Group I means that intravitreal ranibizumab
treatment is effective in preventing recurrence in patients
with stage I RAP. Stage II and stage III lesions seem to be
more difficult to treat, because theses lesions have PED or
chorioretinal anastomoses. This may be one of the reasons
why RAP is known to have a poorer prognosis than neo-
vascular AMD. In the PrONTO study [26], RAP lesions
received 5.8 injections per year, and the number of ranibi-
zumab injections showed a higher frequency than other
types of AMD. In comparison, the mean number of injec-
tions (4.07) in our study seems to be lower than that of
the PrONTO study. But, except for stage I, RAP at stages
II and III received 4.88 injections, which was a similar
number to the one in the PrONTO study, although a
direct comparison is not possible. Especially, patients in
stage I RAP presented relatively few recurrences and
responded well compared with patients in stages II and
III. Therefore, these results showed that the stage of RAP
could be an important prognostic factor.
With regard to the combination of an anti-VEGF agent
with PDT for RAP, Lee et al [32] reported an improvement
in the mean visual acuity from 20/125 at the baseline to
20/63 at the 12-month follow-up of 9 eyes treated with
ranibizumab in conjunction with PDT in stages II and III.
But the fact that geographic atrophy was detected in the
groups having combined PDT with an anti-VEGF agent
suggests that simultaneous combination treatment with
PDT in patients with RAP may enhance photochemical
stress in the normal choroid with prolonged or magnified
hypofluorescence in ICGA because of ischemia in the
Fig. 3 Changes in mean central macular thickness (CMT) of three groups in 12 months
Fig. 4 The total numbers of intravitreal ranibizumab injections given during 12 months of follow-up for 41 eyes with retinal angiomatous
proliferation (RAP) (* P < 0.001)
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normal choriocapillaries. Sometimes photodynamic ther-
apy can lead to significant adverse effects such as massive
hemorrhage, RPE damage and fibrous scar formation;
such complications are a serious concern and cannot be
overlooked.
Rouvas et al [33] reported that lesions that are believed
to be Stage II may in reality be Stage III because of the
presence of small undetectable chorioretinal anastomoses.
We should understand the difference in prognosis accord-
ing to the stage of the disease. In the present study, it is
possible to say that because the mean number of injec-
tions was lower in stage I, patients in this group experi-
enced a lower rate of complications and recurrences in
comparison with patients in other stages. These findings
have important implications in the prognosis of RAP in
that the early diagnosis of stage I RAP is critical in
preventing recurrence of RAP. Although no eye in the
three subgroups showed progression to a higher stage of
RAP during the follow-up, additional therapies such as
more frequent ranibizumab injection and combined with
PDT can be considered in stages II and III.
Conclusions
Although our study has some limitations such as the retro-
spective nature of the study, the absence of a control group,
a small number of patients, and a relatively short follow-up
time, our results suggest that ranibizumab monotherapy
may be a safe and highly effective treatment option for
patients with RAP lesions that are in early stage. On the
other hand, selective individuals in late stage are required
more additional therapies. A larger, controlled, prospective,
randomized comparative study with a longer follow-up
Fig. 5 a Baseline fundus photograph and corresponding OCT image of a 62-year-old woman with retinal angiomatous proliferation (RAP) before
injections. It demonstrates intraretinal neovascularization (IRN) with multiple drusen in the region of the fovea. The initial BCVA was 0.398 (LogMAR).
b 12 months after injection, IRN decreased. The final BCVA was 0.201 (LogMAR). c FA shows a focal area of hyperfluorescence (leakage) corresponding
to the IRN. d After injections, leakage in FA resolved in the IRN. e ICGA shows a focal area of intense hyperfluorescence or a so-called ‘hot spot’
corresponding to the lesion. f One year after treatment, ICGA showed resolution of hyperfluorescence
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period will be required to fully compare differences in treat-
ment efficacy according to the clinical staging of RAP.
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